Markets:

Overview

News

Currencies

International

Treasuries

INmune Bio Inc. - Common stock (NQ:INMB)

1.545 +0.055 (+3.69%)

Streaming Delayed Price Updated: 11:51 AM EST, Jan 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about INmune Bio Inc. - Common stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Peer Reviewed Study Highlights Therapeutic Potential Around Application of Stromal Cell Therapies Such as INmune Bio’s CORDStrom™ Platform

December 05, 2025

From INmune Bio, Inc.

Via GlobeNewswire

INmune Bio Reports New Phase 2 Grey Matter Imaging Data at CTAD Conference Reinforcing XPro1595’s Evidence Base in High-Inflammation Alzheimer's Patients

December 01, 2025

From INmune Bio, Inc.

Via GlobeNewswire

INmune Bio Announces Two Presentations at the Upcoming 18th Annual CTAD Conference

November 18, 2025

From INmune Bio, Inc.

Via GlobeNewswire

Earnings Scheduled For October 30, 2025 ↗

October 30, 2025

Via Benzinga

Earnings Scheduled For August 7, 2025 ↗

August 07, 2025

Via Benzinga

INMUNE BIO INC (NASDAQ:INMB) Reports Narrower-Than-Expected Q3 2025 Loss ↗

October 30, 2025

INmune Bio (INMB) reported a narrower-than-expected Q3 2025 loss, sparking a positive after-hours market reaction for the clinical-stage biotech firm.

Via Chartmill

INmune Bio Inc. to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on Thursday, October 30, 2025

October 23, 2025

From INmune Bio, Inc.

Via GlobeNewswire

INmune Bio to Participate in Dermatologic Rare Disease Panel at the Maxim Growth Summit 2025

October 14, 2025

From INmune Bio, Inc.

Via GlobeNewswire

INmune Bio Announces Submission of Phase 2 MINDFuL Trial Results in Alzheimer’s Disease to npj Dementia, a Nature Portfolio Journal

September 29, 2025

From INmune Bio, Inc.

Via GlobeNewswire

INmune Bio Announces Successful Completion of First Commercial Pilot-Scale Manufacturing Run of CORDStrom™ at CGT Catapult

September 15, 2025

From INmune Bio, Inc.

Via GlobeNewswire

INmune Bio (INMB) Q2 Loss Widens 110% ↗

August 07, 2025

Via The Motley Fool

Topics Intellectual Property

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

August 07, 2025

Via Benzinga

What's going on in today's pre-market session ↗

August 04, 2025

As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.

Via Chartmill

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

August 04, 2025

Via Benzinga

INmune Bio’s CaRe PC Trial of INKmune™ in Metastatic Castration-Resistant Prostate Cancer Meets Endpoints and Is Closed to Enrollment

August 04, 2025

From INmune Bio, Inc.

Via GlobeNewswire

INmune Bio Inc. to Report Second Quarter 2025 Financial Results and Provide Corporate Update on Thursday, August 7th

July 31, 2025

From INmune Bio, Inc.

Via GlobeNewswire

INmune Bio to Publish Video Detailing MINDFuL Trial Findings of XPro™ Presented at the Alzheimer’s Association International Conference

July 29, 2025

From INmune Bio, Inc.

Via GlobeNewswire

Why Celcuity Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket ↗

July 28, 2025

Via Benzinga

INmune Bio Rebounds Sharply During After Hours Trading: What's Driving the Surge? ↗

July 28, 2025

Following the announcement of TNF inhibitor, INmune Bio Inc. stock surged by 24.72% in after-hours trading on Friday.

Via Benzinga

INmune Bio to Present Phase 2 MINDFuL Trial Findings of XPro™ at the Alzheimer’s Association International Conference

July 24, 2025

From INmune Bio, Inc.

Via GlobeNewswire

'Pharma Bro' Martin Shkreli Says 'Good Chance' Inmune Bio Stock Will Slip 90% On Monday ↗

July 04, 2025

Former hedge fund manager Martin Shkreli has issued a stark warning on the near-term trajectory of a biotech startup, just days after it witnessed a surge.

Via Benzinga

Which stocks have an unusual volume on Thursday? ↗

July 03, 2025

The trading volume of these stocks is deviating from the norm in today's session.

Via Chartmill

This Textron Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday ↗

July 01, 2025

Via Benzinga

INmune Bio, Inc. Announces Closing of Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

June 30, 2025

From INmune Bio, Inc.

Via GlobeNewswire

Let's take a look at the stocks that are in motion in today's session. ↗

June 30, 2025

Stay up-to-date with the latest market trends one hour before the close of the markets on Monday. Explore the top gainers and losers during today's session in our detailed report.

Via Chartmill

Crude Oil Moves Lower; Joby Aviation Shares Surge ↗

June 30, 2025

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

June 30, 2025

Via Benzinga

Which stocks are moving on Monday? ↗

June 30, 2025

Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements.

Via Chartmill

Alzheimer's Setback Hits INmune Bio Stock, But FDA Hopes Remain ↗

June 30, 2025

INmune Bio's Alzheimer's drug XPro showed targeted benefits in patients with brain inflammation, but misses the main trial endpoint.

Via Benzinga

Dow Gains Over 100 Points; Chicago PMI Weakens In June ↗

June 30, 2025

Via Benzinga

Topics Stocks

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.